All right, now you can hear me. Well, welcome to Orchestra BioMed's R&D Day 2026. Welcome to those of you who are not in this beautiful room on a rainy day in New York, and thank you for your patience. The rainy day in New York caused us to do something which is critical to our business, which is adapt and be flexible and solve problems. We have done that. We have a great program today. My name's David Hochman. I'm the chairman and CEO and one of the founders of Orchestra BioMed, and I will also be your emcee. Hopefully this works. Oh, it works, but I'm not seeing that. Today is really focused on R&D, but we do have some fabulous recent updates that I'm going to take a moment just to talk about.
We are, I'm proud to say, funded through 2028, following a very successful oversubscribed public offering that we completed last week. We have some new shareholders in the room. We welcome you guys to the Orchestra BioMed family. We had great support from existing shareholders, and we're super grateful that the $80-plus million in net proceeds from that financing, combined with over $100 million we had at the end of the quarter, have us funded to execute on almost everything we're going to talk about today. That includes having just accomplished the enrollment completion of our BACKBEAT pivotal trial, 349 enrolled patients, and we're now really focused on the follow-up. We'll talk about that. We also learned something really important just this week from the FDA.
We confirmed something we thought, which is that we'll be able to, or our partners at Medtronic will be able to submit this as a PMA supplement. We are excited about the acceleration of the Virtue trial, which is going to be actually our first topic today, and that's happening in real time. Having just come from TCT and having an investigators meeting and a coordinators meeting, we really have some great momentum there. What we're looking ahead at is two years of very significant milestones. We just completed one in terms of enrollment of BACKBEAT. We're looking forward to seeing those results, the primary endpoint results, which hopefully we'll present as a late breaker at HRS in May of 2027.
There is long-term follow-up after that, but exciting regulatory milestones that Medtronic will be able to drive in terms of submission, leading to what we think can be commercialization as early as the first half of 2028 in the U.S., and the second half of that year could see global commercialization. In the same time, we're going to be focused on enrolling the Virtue trial. Our target is the end of next year, 12-month follow-up on that study. A rich landscape of catalysts and milestones. Today, as we talked about, is about R&D, not the business. If you're here, hopefully, you may already be a shareholder, but you've heard about our business model.
You've heard about the arrangements we have in terms of what we can do together with Medtronic, but we really want to focus on the science and the clinical research that has driven these programs. We have a great program. We made some adjustments. We're going to start actually with the deep dive into Virtue SAB with Dr. Allen Jeremias. Darren Sherman's going to lead that program. We're then going to do a deep dive with Vivek Reddy and Marat Fudim into the AVIM program. Unfortunately, we had Dean Kereiakes, one of our co-principal investigators, was supposed to be with us, but unfortunately, is not going to be able to be with us today. But we do have another bonus contributor who is a senior clinical advisor to Orchestra BioMed, Duane Pinto.
Duane is the Chief Medical Officer of one of the most exciting private companies in structural cardiology, JenaValve, and he's spending a little time on the side advising us, and we're really grateful that he'll be here and contributing as well. I'm going to do this without knowing what's behind me because this keeps bouncing. R&D. R&D really starts with unmet needs, and we happen to be focused on, and we're going to dive into specifically how we're focused on helping tackle two of the biggest medical problems there are in the world. Hypertension, which is the number one contributing risk factor for death worldwide, and coronary artery disease, which is the leading cause of death. But we have a particular approach to R&D that I want to discuss, and they're consistent across both our programs.
What we first focus on is building on proven foundations, and what you'll see with both of our technologies is we are building on two of the fundamental technologies that have created the fields of interventional cardiology and cardiac rhythm management. With regard to Virtue, balloon angioplasty, with regard to AVIM, the pacemaker. These are technologies that have been in clinical use for upwards of 50 years. What we focus on doing then is creating powerful new capabilities to add to these proven technologies. What we're doing with AVIM is allowing a pacemaker now to be a potent way to immediately and substantially lower blood pressure and treat hypertensive heart disease. With Virtue, we think we are creating a better, superior approach to delivering and extending the release in tissue of a proven drug that will help heal the vessel.
The key to what we do is collaboration. We are realizing the potential of these technologies through collaboration, both with our strategic partners as well as with our research partners. I was here about two years ago, maybe some of you were here. It was a smaller, less well-attended R&D Day event, and it was right when we were getting going with the BACKBEAT trial. One of the things I talked about two years ago is, and this is a great room when you look at the art, you can't see it online, the renaissance that is occurring in the use of these foundational technologies, balloon angioplasty and pacemakers. A renaissance is this beautiful thing of when we look back in time to essentially innovate for the future. That's happening with these foundational technologies. Someone may want to look at this.
It's going in and out. Fortunately, I think I know what I'm talking about. I think we go back with the pacemaker to 1958. We have our colleagues from Medtronic here. I'm going to make them stand up in a minute. But 1958 was the first implant of a pacemaker. For a balloon angioplasty, the first procedure in 1977. Pacemakers are still a fundamental technology. Balloon angioplasty is foundational to everything we do in interventional cardiology, but exciting new things are happening. Pacing, conduction system pacing is really changing the way we think about cardiac pacing therapy and creating a rich, fertile landscape for new treatments like AVIM. Leadless technology, which Medtronic brought first to the market 10 years ago, is entering a very exciting stage of dual-chamber devices.
Actually, we'll talk a little bit about how a single device dual-chamber pacemaker can synergize with our therapy. On the balloon side, we're seeing a renaissance in balloon angioplasty with drug-coated balloons. This renaissance is setting the stage for something. What did the renaissance set the stage for in history? Around the 15th, 16th century, we had all this looking back to the classics to be able to innovate for the future. The renaissance gave birth to something I love, a period in history called the Age of Enlightenment. We've now moved from the last R&D Day to the Age of Enlightenment two years later, okay? In that period, we saw the innovations in the renaissance essentially turn into broader and more significant impact in society, where that invention really spread, both through geography and through different parts of society.
In the Age of Enlightenment, the scientific discoveries, things like Copernicus putting the sun at the middle of our solar system became, with Galileo, the birth of astronomy and other sciences. We had the printing press, which suddenly now we can express information everywhere. We see this same theme, okay? We see our technologies enlightening the renaissance that's occurring around the foundation. With AVIM, we're talking about taking cardiac pacing into a whole new area, being able to envision treating hypertension and hypertensive heart disease at the same time as we treat bradycardia, allowing the same device for the same patient to have more impact, while also opening up the potential to treat more patients. The same with Virtue.
We're taking proven technology, both the procedure and the drug, and now creating a much better way, in our view, to make that available to tissue, both in the artery and eventually beyond, and we think ultimately improve vessel healing and improve the clinical outcomes for patients. These are big ideas. Something else happened in the Enlightenment. There was a creation of the symphony orchestra, and that too was driven by innovation and by visionary leadership. It was about new instruments, new training for musicians, new ways of being able to teach music and actually notate music, new ways of thinking about putting groups of musicians together. But then there was this guy, Monteverdi.
If you're a student of classical music, and I'm a real amateur, he had this idea of, "How do I take all of these innovations and bring them together to allow music that we've never heard before, essentially music of a whole another level, but be able to transport that music from city to city, from royal courts eventually to music halls so everyone could enjoy it?" The thing about that symphony orchestra that inspired us is the idea of extraordinary collaboration. I'm going to have to turn to read it because it's one of my favorite quotes. Now I can see it. "What more miraculous creation of mankind is there than the symphony orchestra? A hundred musicians collaborating flawlessly in the creation of a single sonority.
From moment to moment, we tend to take for granted the skill and sensitivity of such a performing organism, and we should take time to marvel afresh that such a joint effort is possible for human beings so rich in communication, beauty, and meaning." A symphony orchestra is really a collection of extraordinary, talented people, the best people in their field, but coming together and sublimating their individuality to create something beautiful together. We are not called Orchestra by accident. We're called Orchestra because that is what it takes to bring these type of innovations to reality and to patients. Our orchestra looks a little different. We are, I'm proud to say, over 100 people in Orchestra today, working across R&D, both on the device side as well as on the pharma side.
You may think of us as a device company, but core to the technology we're going to talk about first is true innovation in how do you protect a drug that works wonderfully in the body for extended release and focal delivery. We have phenomenal people now in our clinical operation, our field clinical operation, that have driven the BACKBEAT trial and are driving the Virtue trial. Cutting across that are other skill sets, from marketing skill sets, regulatory, and finance. I am incredibly proud of the Orchestra organization that we've built. This organization then partners with amazing physicians, we have some with us today. Amazing research staff. We frankly see our patients, we underestimate the patients we are seeking to treat are a partner in the innovations that we are bringing forward.
We have 349 that are part of the BACKBEAT trial, but a lot more that wanted to be and hope to be part of the trial. We have an ambition to bring another 740 patients into our Virtue trial. Core, and lastly, to our business is a focus on strategic partnerships with world-leading companies that allow us to think about how are we going to optimize bringing these technologies to patients globally. We have our partners from Medtronic, Dr. Rob Kowal, Chris King, Matt Schold from Medtronic here. It is because of that partnership that what you're going to learn about with AVIM can unbelievably quickly, when you think about in the scale of treating and changing medicine, become a reality, assuming we get the data that we hope to see out of the trial.
It's that collaboration that allows us to focus on being best at what we need to be best at, innovation, clinical execution, thinking about how to bring together a small company like Orchestra BioMed with a global leader like Medtronic, and leveraging what they have built over the last many decades that makes them the leader in this field. With that in mind, I have now the privilege to introduce a person without which any of this wouldn't have been possible. My business partner, my co-founder, the President and Chief Operating Officer of Orchestra BioMed, who has been core to the development of both these technologies from the concept stage, and that's Darren Sherman. He's going to lead us through a deep dive with Dr. Allen Jeremias into the Virtue technology. I'll come back for our discussion, and we'll get back to the AVIM program. Thank you guys so much.
Or similar or higher. It is incredibly great to be on this stage and talking to you. I am tone deaf and know nothing about music. But the orchestra is really important to me because it is about the collaboration and the people and finding ways to get together. Following David is an honor and a privilege, and we wouldn't be here today together for a long time. But I want to talk to you about Virtue. Virtue is truly a great name for this product, and it's where we're going with it. But to do that effectively, we have to kind of maybe go backwards in time, and we got to talk a little bit about the history of interventional cardiology and the treatment of coronary artery disease specifically.
It really starts in 1977 with balloon angioplasty, the first treatment that could be non-surgical treatment to open up arteries and prevent cracking. Amazing, great for patients. Not perfect. Restenosis rates or reintervention rates were high. Sometimes patients would come back, and physicians didn't love the idea that they'd come back with a block closure or a sudden closure of the vessels. The innovation of thinking I can put a permanent metal implant into your artery comes next, because I can solve two things with that. I can prop that artery open, prevent abrupt closure, reliably walk away and not worry too much after the case, and reduce the rate of reintervention a little bit. 2003, with the launch of the first drug-eluting stents, it takes it to another level. The drug is not there to treat the disease.
The drug is there to treat the injury of the stenting and the angioplasty, and it dramatically changes medicine for the last two decades, with millions of patients benefiting from that. What it really did was provide a source for the drug to get into the tissue, limit proliferation of cells, and allow patients to reduce that first-year restenosis rates. Unfortunately, you signed up for a lifetime of having a stent. Both a bare metal stent and a drug-eluting stent is a lifetime of having a foreign body in your body, which 2%-4% year-over-year risk, not just of reintervention, but of MI, stroke, and death. We dramatically changed things to improve, and we traded it off with that permanent implant. Today, in the last two years, is the first entry of drug-coated balloons. It's going backwards to go forwards.
It's relying on the first balloons, but taking those drugs from those drug-eluting stents and delivering them to the tissue from the surface of that balloon. Remarkably, we don't need it, because abrupt closure hasn't been seen with these drug-coated balloons in thousands of patients, including in clinical trials, because pharmacotherapy changed over the last 30 years. If you don't need the scaffold to prevent restenosis, if you don't need the scaffold to prevent a blood closure, you're really relying on the scaffold for drug delivery. With new drug-coated balloons, we're trying to deliver the same drugs we used in stents, but without that permanent implant there to continually provide a source of that drug to the tissue. It's tricky. Okay? I'm getting yelled at. I'm too wide. You can't see the screen. Thanks, David. Thanks, man. This drug-coated balloon evolution is really getting exciting here now. Why?
Because the first drug-coated balloons in the U.S. got approved about two years ago. At TCT, half of the content in the PCI track is only about drug-coated balloons. Right now, in the first year since launch, about 25,000 patients, or a quarter of all the in-stent restenosis cases in the U.S., already happened in the first year. But one-third of cases happened for non-ISR cases, not the indication, but for clinical need. Drug-coated balloons have been available outside the United States in pretty much every geography for more than a decade, and we're the last to come to market from it, because FDA was so concerned about how much drug, where does it go, is it creating downstream particulate, can it reproducibly be produced? A challenge. But the excitement level is high, and rightly so.
Can we move on to an era of leave nothing behind, and do we really need to put more metal in? Going to Renaissance and Enlightenment. We're here with Virtue taking two key pillars, balloon angioplasty, 1977, and the use of an mTOR inhibitor, sirolimus or rapamycin, dating back to the first clinical uses in 1993. The drug itself could questionably be the most studied drug. If you go to clinicaltrials.gov and you do a search, it is amazing how many places and what it's done. But what's not happened with it is no one's really developed a long-acting version of it. It's always systemically delivered or it's delivered from a stent, which provides a depot, a long-term permanent depot. Virtue is taking this concept, which has revolutionized interventional cardiology, a different direction.
A stent is a surface delivery where the drug has to diffuse out of the stent and diffuse through the tissue. A drug-coated balloon delivers the drug to the intraluminal surface and has to diffuse from the surface into the tissue. I am not a strong human. When I go to the dentist, I'm not going for the topical lidocaine. I'm going for the injection. Why are there drug injections of lidocaine, and why is the topical not good enough? Because it's really difficult to get a topical to get a high enough dose for long enough. An infusion is what's required. That is what we're doing with Virtue SAB. It's the first of its kind novel approach to deliver transmural infusion of these drug particles. These drug particles are not uniform in size. They immediately saturate the vessel, small particles proximally and more closely to the inner lumen.
The largest stick there, smaller ones go through. But importantly, with a large liquid volume, we are able to distribute into the vessel wall and beyond the vessel wall circumferentially and longitudinally down the vessel. If we use drug-eluting stents as a marker, they deliver over about 28 days, one nanogram per milligram tissue. That is a drug concentration in the tissue through diffusing from this permanent implant. We are delivering a tenfold dose instantaneously and maintaining that tenfold dose over the elution period. We are doing an injection into the vessel wall itself of the vessel as an infusion, not a diffusive topical delivery. Here is a short animation giving you a little bit more about Virtue for those that are not familiar. If you guys could run that, please. The balloon goes in as a normal balloon. It has micropores in the balloon.
The balloon gets delivered to the lesion without rushing, and as it gets to the lesion, you use the drug itself to inflate the balloon, and it comes through the micropores of the balloon. These particles, these small particles travel through the balloon into the tissue, surround it, and distribute along it. But importantly, these particles now become the source of diffusion of the drug, not from the surface, but inside the vessel wall itself, in the inner side of the vessel wall and throughout the vessel wall. This is not a drug-coated balloon, and this is not a drug-eluting stent. But it is foundationally based on a balloon and a drug that works. This is not a new technology. It is a brand new technology. Because we are leveraging the past, we know this drug works. There is not a binary risk of, does this drug worsen this indication?
It is in millions of patients. It is not a question of that. It is a question of, can you mimic what a stent does without a stent? Can you deliver a high enough dose for long enough? No one has been able to do that, and that is what Virtue does. If we think about this, the particle and the drug formulation is the innovation. It is the ability to create a long-acting sirolimus, a long-acting mTOR inhibitor that you can deliver locally and focally. The balloon is the familiar. It is allowing the interventional cardiologist to use something familiar to put an injection to the vessel wall. It is one version of delivering an injection, not a syringe or another device. It is an example of delivering a local acting into where you want it to go.
Think of all the applications where you wish you could have a long-acting mTOR, where mTORs already been either studied or approved by systemically dosing or long-term dosing. But they cannot get high enough doses for long enough locally. That is what we are doing here in this trial. Not the third or fourth drug-coated balloon, the first infusion of a long-acting drug. And the innovation is the drug itself, the pharmaceutical component, and it gets to leverage a really big history where this drug has been studied. We are now enrolling this trial, 740 patients, and it is a one-to-one randomization versus Boston Scientific's AGENT drug-coated balloon, the market leader and the first drug approved in the U.S. But it is more than a one-to-one with AGENT, because it is comparing sirolimus to paclitaxel. We will talk about that difference, and it is big. It is not just comparing sirolimus and paclitaxel.
It's comparing surface delivery, a topical- to a long-acting infusion. We're enrolling these patients, looking for a 12-month target lesion failure follow-up, looking both as non-inferiority with a test for superiority. With this, I'd like to introduce Dr. Allen Jeremias. He is a special person who's come to us, thankfully, to join the Orchestra. He's here because he's an expert in physiology, an expert in imaging, a thought leader in how to improve complex PCI, but he's got a mind that thinks differently and wants to understand differently. Not that he blindly believes. He wants to question, ask, just like we do.
He's been recognized by his peers in SCAI and CRF as a top interventionalist, but to me, he's an example of the people that joined our team, a good human being, a hardworking person who I've had the pleasure of talking to almost daily since we've been engaged in this. That's special, and I want to thank him for being here today, and he gets the pleasure of trying to touch slides on a screen that you can't read.
Thank you, Darren. Hey, David, thanks so much. Well, I think it is somewhat interesting. I know it might be a little dry. You're talking a lot of cardiology, interventional cardiology, but let's see how we get through this. The original or the main indication, really the only on-label indication, if you will, currently for this technology is in-stent restenosis, right? In-stent restenosis is not a small problem. We do about 1 million PCIs currently in the U.S. alone. About 10%, a little over 10% of patients come back year after year after year with in-stent restenosis. So, that's obviously a pretty substantial number of patients when you think about how many stents are implanted in this country alone, it's about 1.6 million a year.
What happens is that when you come back with in-stent restenosis and you already have a failed stent, right, there's a reason why the stent failed, now you're faced with the option, are you going to put another layer of stent? Are you going to continue that path, if you will? Or you do something else, and I think since we have the drug-coated balloons available for maybe a little over two years in the U.S., as Darren mentioned, Boston Scientific's AGENT balloon was the first approved. We now have a second one. Obviously, this has been now kind of the default therapy, but that said, these patients don't do great, right? If you have a stent failure, your chances of coming back is actually pretty substantial over the next, I don't know, four or five years.
Even when you are looking at the de novo group, even those patients do not do great, right? Because you have this permanent implant. This whole mindset, now that we have this technology available in interventional cardiology, has shifted more towards what can we do for lifetime management, not to get out of the room today, to get the patient off the table. How can we help this patient for the next decade, two decades, three decades, as we all probably going to age to a lot longer than previously? Not leaving something behind is a very appealing concept. Let us talk about the two major drugs that are out there on coated balloons. One we talked about, sirolimus, the other one is paclitaxel. We had this history before, about 20 years ago, when the drug-eluting stents came first along.
We had two drug-eluting stents, and for a couple of years, they were about used 50/50, right? Over time, we discovered that sirolimus is a much, much better drug. When you are looking at the left, you see that there is a much lower risk of target lesion revascularization. Overall major adverse cardiac events are reduced by about 25%-26% with sirolimus compared to paclitaxel. When you are looking at, I guess, history, what happened was that paclitaxel really fell off the cliff, right? Nobody is putting this on the stent any longer now that we have better technology available. Currently in the market, every single drug-eluting stent is coated with sirolimus. One of the main reasons is that, let us just be plain, paclitaxel is just cytotoxic, right? The therapeutic window you have is very, very narrow with that.
Versus sirolimus, is cytostatic, obviously big, big difference. It is arresting smooth muscle cell proliferation, which basically means we are creating injury when we do angioplasty. It just goes with the territory. There is no way of not kind of tearing the tissue apart, if you will, to a certain extent. The body reacts with proliferating smooth muscle cells. That is kind of the normal response, which is what the Achilles heel was for interventional cardiology the time before we had the drug-eluting stents. It is important, obviously, to arrest that and also modulate inflammation. A lot of diseases are inflammation modulated, but in particular, when you introduce an injury to the vessel, of course, you have a huge inflammatory response. Having a broad therapeutic window, having potent anti-inflammatory response, I think those are the main advantages of using sirolimus.
That said, the major disadvantage is, it is very, very difficult to get it into the tissue, because it turns out paclitaxel actually is lipophilic. So it is actually easy to blow up a balloon and just get the paclitaxel into the tissue, versus sirolimus, you have to do a lot of modeling, which is, I think these guys worked on this for a decade, two decades? Too long. Let us just say it was too long. Whatever, how long it takes, right? But they developed something incredible, and sometimes it takes time to build something special. But the bottom line is, if you just put sirolimus on a balloon, none of it will penetrate into the tissue. That is really the problem.
I think we have a very, very interesting example, kind of a natural experiment, if you will, which is an old stent, the Endeavor stent, which since fell out of favor. It was a Medtronic stent at the time. It has been now replaced with the Endeavor Resolute. The interesting thing about it is that Resolute, which is a current stent that we use, uses the same drug, it is the same stent. The only difference is the polymer, right? The polymer of the original Endeavor just released all of the sirolimus in the first couple weeks or so, and it just was not a high enough tissue concentration for long enough to basically inhibit this response we just talked about. Versus the current polymer, of course, is much, much better.
As you see all the way on the right, it has now released of sirolimus up to 180 days. The difference is on the right in terms of the outcomes. When you are looking at in-stent lumen loss or target lesion failure, it is substantially higher with the original Endeavor stent compared to the current technology. So that is kind of the proof of principle how important it is to have sufficient tissue concentration of sirolimus in the tissue to inhibit this inflammatory response. One of the things we know about the current generation drug-coated balloons is that there is just only so much smear you can put on a bagel, right? You just cannot put more than a bagel is holding. That is the fundamental limitation when you have a balloon, right? You put as much on as you can, but there is only so much surface.
To make things worse, it is sitting on the outside, right? It is not inflated, but still sitting on the outside. You can imagine getting it to where you need to go sometimes is not easy. Sometimes you have to cross tortuosity, sometimes you have calcifications. It is not necessarily that it is easy to get the balloon. In some studies, up to 80% of the drug was lost in transit. When you only have so much surface to put drug on and a lot of it is lost in transit, how much do you actually have to deliver? Then what happens is that the delivery is uneven, because in some areas of the balloon, maybe some of that drug was shaved off, and so you are going to have less delivery in one area. In other areas, you might have a bit more.
It is a topical, just like Darren Sherman said, like it is lidocaine cream. So even when there is drug available, only so much penetrates into the tissue. As a consequence, this is basically the drug concentration in the tissue. Let me get back to the slides that I think Darren Sherman showed before. This is a very, very important thing to remember. You do not have to be a biologist, but remember this one thing, that if you want to have potent inhibition of the inflammatory cascade post-PCI, you have to achieve a minimum of one nanogram of drug in the tissue per milligram of tissue for at least 30 days, better even for 90 days. This is a logarithmic scale, right?
When you are looking at the current generation sirolimus-eluting DCBs, which is MagicTouch and SELUTION, you see the drug concentration at 30 days is much, much lower than this one nanogram benchmark. Stents are around one nanogram, right? When you are looking at the outcomes of the clinical trials, this is the SELUTION trial, the event rate was 16%, which is, I guess, non-inferior to standard of care, which is what the trial showed, but ultimately certainly not a result that we would be happy with as clinicians. Now having this fundamentally different approach to drug delivery, to actually being able to deliver a large liquid volume of infusion and getting the tissue concentration to much, much higher levels really changes the ballgame here.
To have this sustained release of sirolimus is obviously critical, and I am going to show you a couple more slides in a minute in terms of the binding sites, how we literally overwhelm the binding sites for sirolimus and completely saturate it, which is actually shown here on the bottom right. You see a drug-eluting stent binds about a third of the sites or so. Virtue SAB has a tissue concentration of 13 nanograms, another logarithmic scale above the drug-eluting stents. As you see, it fully saturates the sirolimus binding sites. This kind of delivery mechanism is actually very, very important and crucial, and it matters also, or the main feature actually is the size of the particles, right? Sirolimus in itself cannot get into the tissue, so you have to have some delivery mechanism. We are not now talking about nanotechnology, right?
These particles are a magnitude smaller than we currently have on the current DCBs, which is measured in micrograms. What we have available right now is the micrograms. This is nanograms. Obviously, it is another magnitude smaller, and so it allows much deeper tissue penetration. It is not just about how much drug we deliver, but also the size of the particles. Interestingly enough, even though all of this is nanotechnology, there is still differences in particle sizes. The larger particles kind of stay at the site of the injury in the subintimal area, but then the tiny little particles, if you will, they actually travel longitudinally, which is really important because now we can not just cover the area where we balloon, but also a little bit longer.
I am going to show you some examples from some of the data that we have, how that makes an impact on the actual angiogram. This is what I was talking about before. When you look at the right, XIENCE, the leading drug-eluting stent. Sorry to the Medtronic folks. Shouldn't have said that. It basically delivers what we ask it to do, right? Early on in the first few days, you get up to 10 nanograms per milligram tissue concentration at 30 days, and up to 90 days, it stays around one. It delivers what we actually need, although, again, we have obviously some in-stent restenosis even in those stents.
But when you are looking at the left with Virtue SAB, you can see now early on, it goes up to 100, and then later on to about 10, and this is where it stays up to 30 days, and then it reaches out to 90 days at those concentrations as well. So, a magnitude higher in terms of the tissue concentration of sirolimus. This is the data that we currently have upon which the current trial has been based. It is called the SABRE trial. It was done in Europe in 50 patients, multiple sites, multiple countries, as you see here.
There was an independent core lab and DSMB adjudicating all of these cases and evaluating these cases, and there was a primary safety endpoint at 30 days, and then a mandatory angiographic follow-up at six months, which is important in many trials because, as you probably know, when you come back for an angiogram, even the patient might be asymptomatic. When you see a restenosis, you might treat it. So trials that have mandatory repeat angiograms at six months or one year have usually higher event rates than those that have only clinical follow-up. So this is the trial results. On the left, you have intention to treat, which basically includes the entire population. As you see, target lesion failure all the way on the right is 12%, which actually is very, very good, again, with the angiographic follow-up that was mandated.
Then almost incredible, between year one and year three, there were virtually no additional events. So the three-year event rate was 14%. On the right is the per-protocol number, and so 36 of those patients that were enrolled, the protocol actually was followed, which means that there was no violation of the exclusion or inclusion criteria, the procedure was done properly, and so forth. So among patients who fulfilled all the criteria of the trial and the procedure was done correctly, when you are looking now at target lesion failure, it is 2.8%, and at three years, 5.6%. Really numbers that are unheard of. This is now a trial that is about a decade old, so the technologies are also not the same in terms of the vessel prep, which also is critically important.
I think in the future, when we hopefully come to an era where we are not going to leave anything behind, the vessel prep is going to be as important as the drug that we deliver. So those will be the two elements that kind of determine your long-term prognosis. That said, in this case, even with the techniques we had a decade ago, the outcomes on the per-protocol basis are really incredible. When you compare that to the AGENT DCB trial, all the way on the right, the target lesion failure at three years was 32%, obviously vastly different from the trial results of the SABRE trial. So these are some of the cases that we studied and we learned about. So this is on the left, a right coronary artery. If you have seen an angiogram before, there is pretty significant in-stent restenosis up to 80%, 90%.
In the middle, this is post-treatment, so this is vessel prep and also delivery of the drug via the Virtue SAB, and then the six-month follow-up. You can see that, if anything, the vessel is bigger, right? What we're looking at here is LLL, late lumen loss, but that's an angiographic core lab measure. Normally what happens is that we implant a stent, let's just say the patient comes back six months later, and there is some degree of intimal hyperplasia, so there's some degree of lumen loss. That's what lumen loss is, and that's how it's measured in the core lab. In this case, as you see, it's subtle, but it's a negative number, which means the lumen actually is larger than we left it behind after the initial procedure, which is kind of a little unheard-of phenomenon, if you will.
This is another example of a mid-LAD. Again, tight stenosis up to 90% in the mid-LAD. Post-lesion prep actually is a very, very good angiographic result. You see post-Virtue, it might look actually a little bit worse than immediately after prep, which is interesting, right? The reason why we think this happens is that this is actually the drug infusion into the tissue, right? So there's a little bit of haziness as you infuse this drug. At six months follow-up, look at how incredible this looks. Not only that, when you're looking at all the little side branches, those are the septal branches coming off the LAD, there is a lot more blood flow in the entire tissue. Both proximal and distal to the treatment site, it seems like the vessel also plumped up, right?
As to the concept that some of those nanoparticles distribute alongside the vessel. The last case I'm going to show you basically shows the same thing. Again, the stenosis in the mid-LAD, and you see all the way on the right, the six-month follow-up, again, a negative late lumen loss number. The vessel actually grew over time. Based on those results and everything else we explained, we're actually very excited to now be in the enrolling phase of the Virtue ISR pivotal trial. As Darren mentioned, a total of 740 patients will be randomized to either Virtue or AGENT paclitaxel, with a primary endpoint of target lesion failure at 12 months. There's no mandatory angiogram, obviously, in this case. The analysis is interesting. It's a non-inferiority study, right? First we want to make sure we're not inferior to AGENT, of course.
If we meet non-inferiority criteria, we move into superiority testing. We're obviously optimistic that we can show for this particular device superiority over the current standard of care. Patients will be followed out to five years. This is the summary. Virtue SAB is really the first of its kind in terms of being able for the first time to have a large liquid infusion of sirolimus into the tissue. It saturates virtually 100% of the binding sites, unlike even with current drug-eluting stent technology. It has sustained sirolimus release over up to 90 days. We're moving into the clinical trial, as mentioned, and we'll hopefully be able to get some data in, when? Couple years? All right, guys. Thank you very much.
Have a good day, okay?
Thank you. Absolutely. Bye now.
Kind of a little round table discussion here. We are going to take questions at the end. I want to remind everyone we have this QR code.
Hi.
Is it okay?
Sorry, put your slide also.
Hold on.
Okay.
We got to turn that mic off.
Other slide. I mean, it's all just delay from the weather, so it should still be going, they said.
Let's turn on the mic in the other room.
All right. We will take questions at the end. We're going to have a little discussion here. Darren's going to kick off.
I guess, Duane, Allen, I think the first real question here is, the world has seen DCBs and had it for a while. The exuberance today that's going on, like, what's really led to that? Why is drug-coated balloons and why is this topic, and why is it on everyone's thought process today in the U.S., and is it just U.S.-centric, or what's really driving DCB as a category right now?
Well, I'm Duane Pinto, so I'm an interventional cardiologist. I also am the Chief Medical Officer of Yenna Health. But Allen and I trained at the same hospital, so perhaps we have the same strategies. But stents were the best that we had. That's no longer the case because we see the downside of those devices, which are in-stent restenosis, which Allen went through beautifully, and stent thrombosis, which is a life-threatening illness. These are man-made diseases. So, if we don't have to leave something behind in order to avoid restenosis, that's a better mousetrap. So, we're actually behind in the United States compared with Europe because they had it before us. So, we were kind of with envy seeing what was happening there and all the new strategies that were being pursued with regard to repairing coronary arteries.
We are catching up now, and I think that's the exuberance that you see, and that's the off-label use also that you have seen, because we've seen what things are capable of outside the United States. But, Allen?
Even beyond the potential complications of stents, I think this concept of caging the vessel and inhibiting vasomotion, because it's a biologically active thing, it's not just a pipe, right? The vessel actually is a biologically active thing, so it has an endothelium. The endothelial function is important. Nitric oxide causes vasodilation. All of these things are important, and we inhibit this basically for a lifetime, right? Especially in a younger person, when you're living with a stent 30, 40 years, I think that's a problem. Also, what we have learned is that you develop recurrent disease. So, there's a reason why you have a stenosis in a particular point in your artery. If you live long enough, five years, 10 years, 15 years, you're going to develop recurrent plaque.
It's not the stent's fault that you have plaque build-up, but you're just going to have plaque most likely or very likely in the same spot. Now, coming to the lab, it makes our life much more difficult because now treating this disease where you have not just plaque build-up, but also kind of a caged vessel with a stent, limits your options, I would say. I think this is kind of almost a revolution in a sense, right? That we use, you showed the slide, about a third of patients get DCBs for non-indicated lesions, which is outside of in-stent restenosis.
I don't want to take over the moderator role, but I just want to ask Allen one question. You mentioned it, and I thought it was important, is you've kind of described how currently optimizing PCI is different than it was in, say, 1990, when perhaps the stent was highly optimized. The reason why drug-eluting balloons are perhaps more likely to succeed and are going to succeed, what's your thought?
Yeah, two reasons. I think one is the prep, right? We have better understanding of how to treat a vessel without actually putting a stent in. Most importantly, medical therapy, right? Because the main issue we had in the early days of angioplasty, patient coming back in the middle of the night with a closed vessel, I think with the current antiplatelet therapies that we have and everything else that we do, that is very, very unlikely. In fact, there are two large randomized trials now for de novo DCB, and it has not been seen at all.
I personally, sorry, I was going just my own take here. I find it fascinating that this groundswell of improvement is in the face of data showing that the first-year restenosis rates of drug-coated balloons is actually worse than a stent. So you are really playing off of putting a worse first-year therapy in to avoid the long term.
Right.
You make those choices every day, right?
In honesty, I obviously realize that, right? Because we can read also numbers, although we are doctors.
These guys are the numbers guys.
These guys are the numbers guys, I guess.
Very scary, actually.
I would say in many cases, if not most cases, we now make the decision that we accept a little bit of a higher vessel, target vessel failure, meaning they're coming back with recurrent restenosis, but we don't put a second layer in. Because putting a second layer is even worse than the first layer, and now coming back, we're really out of options.
But you would agree, sorry, I'll let you in, but you'd agree that we're still in the early days of truly getting to drug-coated balloons. I don't think you're satisfied with the results today. I think people are looking for improvement, right? It's not like, "Oh, I'm coming with another one." It's, we need to grow and build on what we have and make it better. I think that's a key thing, right?
Yeah. I mean, I think you see the appetite for better. I mean, we'll take an early penalty to not leave something behind because we've reduced the options of patient by putting a stent in. So them coming back, and then we decide what to do, is a better choice. Now, if we had something that wasn't worse in the first year, that's a home run, you know?
Yeah. I remember our first meeting, Allen, and we've obviously spent a lot of time together. But I think as you've now not just understood our technology better, but now had the opportunity to treat patients with it, what do you see as that in terms of what's the expectations you have for a technology like this? And what excites you about it? And to Duane's point, in terms of thinking about a future where we can build on this leave nothing behind concept, but with better technology. What are the advantages that you're seeing, and what are you hopeful in terms of the Virtue trial?
Well, I mean, based on all the data we just went over, nobody can predict the future, but obviously we're optimistic that this is going to be a complete game-changer in terms of the recurrent restenosis or even de novo disease. It will fundamentally shift how we treat patients if we have this available, and we, let's say, we get a decent vessel prep, which happens in about 80%, 85% of patients. So let's say there are still some patients where you need a scaffold, right? But in the vast majority of cases where the vessel prep is adequate, and now you have a technology like this where you can deliver industrial doses of sirolimus into the vessel and completely block the inflammatory response, it's a complete game-changer.
In terms of not getting adequate drug delivery or adequate treatment in terms of treating particularly coronary stent restenosis, I think, what are the downsides? What happens if we don't really get adequate coverage, we don't get adequate healing? I think it'd be good to bring to light some of the challenges that we see in terms of treating essentially a restenosed stent if we aren't getting that drug effect.
Well, I mean, if we can't inhibit this process and we create a lot of injury, so treating in-stent restenosis is actually difficult, right? Because there's, again, a reason why the stent failed. Now we go in with bigger devices, we go with higher atmospheres. Sometimes we use intravascular lithotripsy, sometimes we use laser, we use different devices. So we introduce a lot of injury in the vessel to now basically clean out as much of that tissue as possible and open the stent as much as we can. Based on that, you need some potent drug coverage, otherwise you're going to have recurrent in-stent restenosis.
I mean, I want to make two points that are related to what Allen just said, is it's much more difficult, much more expensive to treat somebody who has in-stent restenosis, period. But also most important to me as a physician are the curves that were shown that major adverse events when you have restenosis are higher. So 30% of these people are presenting with heart attacks. So we're giving them a disease to, quote, "prevent a heart attack," and we're giving them a more chance of having a heart attack. That's not a good trade for me. So we've taken somebody whose major problem was angina, might not have ever turned into a heart attack, now we've given them a risk to have a heart attack. So I'm not good with that trade. I want to have us helping patients in the long term.
I'd like to take We talk about dose, we talk about dose concentration. You showed what I think are remarkable images that core labs have reviewed and seeing not just the lesion improve, but seeing the vessel improve and seeing septals and side branches grow, and it is ultimately about perfusing the heart and making sure it's perfused. Is that a normal thing you've seen? I mean, like, I stayed at a Holiday Inn. That's not normal, right? Do you guys see this? And what does it mean by having an infusion that could go beyond the edges, and what could that mean?
Yeah, that's a good point. What happens frequently, the longer your stent is, of course, the higher your chances are of restenosis. Frequently what happens these days is that people come back that have long stents, two stents, three stents. A good portion of it is restenosed, of which you might only treat partially in a sense, because the DCBs are, I wouldn't say cost prohibitive, but very, very expensive, right? They are 10 times, more than 10 times more than a stent. You're using a balloon, let's just say a drug-coated balloon that is currently available, that is 30 millimeters long. Now, we have a 40 millimeter stent, balloon coming out. There is certainly areas to leave behind, right? The edges in particular are not fully covered.
These are all areas where there is a good chance they might have recurrent in-stent restenosis. Having a technology like this, for example, where you not only have high tissue concentration where you actually inflate the balloon, but with these nanoparticles we talked about that also longitudinally distributes in the vessel, you might indirectly actually also treat this entire segment. I think this is what you were referring to when you're reviewing these angiograms from the SABRE trial, that this entire segment looks, not just the lesion itself, but the entire segment looks better, looks bigger, the branches are better perfused, and so forth.
I don't want to scare you guys when it comes to describing how angioplasties and stents are done, but I'm just going to do it anyway. When we're faced with a blockage, we inflate a balloon first and smush it open, and then we put a stent in hoping that we landed in the same area we just injured. That's what Allen is talking about. If you miss, that's called geographic miss.
That's what happened to me, but I-
Well, when we were doing cases together, how the state-of-the-art was, what do you think?
Yes, that's true. What do you think?
What do you think? Did we get the spot? Did we not? We're like-
Probably.
Two times zero is still zero. Still, we both agreed, then that's why people come back with edge restenosis, is because we didn't cover the area. You don't have to worry about that with Virtue, because when you do have to worry about it with the drug-eluting balloon, because it's just like right there. If you can get the whole segment, then you indemnify yourself against, did you get it? That way we can also not have to choose between leaving a 10% lesion behind and do we cover that with a longer stent, because it's just a math equation. Do you put in a longer stent with more restenosis, or do you leave a plaque behind that you think might not never get there? If you can treat the whole thing, then I think that's a better mousetrap.
I just want to add a comment, because one of the things that, in addition to drug-coated balloons being probably the most prolific topic at TCT, you guys are both imaging experts. We are getting better tools for intravascular imaging. We are getting amazing tools for non-invasive imaging. Some of the things that used to happen, I think are going to be a lot more evident as we move into the next 10, 20 years of treating artery disease. Did we do a good job? We are particularly excited about having a tool that hopefully has that broader reach, that deeper drug delivery, and has that effect, particularly since the tools we are going to be able to use to actually see the underlying disease and see the result after are getting better and better.
Yeah. For me, the satisfaction, the curiosity, the interest in this is really about not just preventing cell proliferation, which paclitaxel has shown that it can do, but really getting inflammatory responses beyond it. If you think of improving the vessel caliber beyond where the lesion site you treated is, it is unlikely that is proliferative. It is more likely that is anti-inflammatory upstream and downstream. As a physiologist and as a scientist, that is fascinating.
Yeah, because we do not have anything like that. We do know from the legs that outflow is important for disease progression proximally. We have not had something like that. I do not know, Allen, you should comment, but we have not had something like that that can improve the outflow of stents without having to put another stent in. We have just been trapped.
Well, I think what is exciting about this technology altogether is that we are just scratching the surface with this trial we are doing for in-stent restenosis. When you really sit down for five minutes and think about all the potential applications for this, right, which is peripheral disease and other, not just the heart, obviously. How many diseases we have are inflammatory in nature. If you find other ways to deliver this, you could treat. What else can you treat, Darren, with this?
You can dream.
We have more than dreams. We have a lot of ideas.
That's plans.
Well, we have some new money. We're going to carefully put it to work. But I think one of the things about that that's interesting is we are not constrained, to Darren Sherman's point, by Even though we built it on the foundation of the familiar, we're giving physicians a tool of essentially a plain balloon that can convert in the procedure to a drug infusion balloon. That was difficult to develop as a first generation. It's going to be a great product. But the idea to what you're pointing out of being able to optimize a delivery system for each application, even beyond in the artery, one of the things we aspire to with some of our next generation devices, can you treat multiple lesions without having to bring the device out?
When we think about other places in the body where we can go, so much of either your post-intervention is managing the healing response, which is what this sirolimus formulation, SirolimusEFR can potentially do. Then there is primary indications. I just had, I have tendonitis two different places in my right shoulder. So I had two deep injections of steroids. They are working. There is no pain. You think about all the people that have, raise your hand in this room if you have had a steroid injection somewhere in your body. Okay. Eventually, some places you can only have two or three because it begins to break down the connective tissue. It does not always work. Can we get sirolimus in play in an indication like that as an application we have thought of? By the way, that does not need to be a fancy device.
That can be the off-the-shelf tools that we have. We do have a lot of ideas. We are focused on, as you said, execution of the trial that Allen's the PI.
Yeah, the genius is not the-
We do not want us to go, be distracted, right?
Right. The genius is not the balloon with the holes in it. The genius is, I guess, the formulation-
It is.
of the drugs.
It is. That's-
Yeah. I mean, there is
That is the pharma team we have in our Orchestra BioMed that we are really proud of.
Yeah. I mean, any -itis basically, anything that ends in an -itis is something that we look, that would say is good.
As somebody who has spent my whole life thinking about innovation and creating new products, it is so much more satisfying to build on the strength of clinical and science of somebody else. This is not a new drug, and it is not a new drug that has not been studied lots of places. It is just a drug that has not been able to be delivered focally and stay there long enough. It is not the binary risk of, is this drug good or bad, or is it safe or not? It is, can you deliver it where you want it to go for long enough? And it just so happens that that is what we are doing here in this trial, and just the beginning.
So we're going to pause here. We'll take a break. I think we'll give everyone a chance in the room if you need to use the restroom or something. We'll come back in 10 minutes and get started on the AVIM therapy program. Once again, if you have questions, we're going to come back at the end with our physician speakers, and we're going to address as many questions as we can. Thanks so much. We'll take a 10-minute break.
[Break]
It seems to be, but I am not sure. Is someone up? Thank you.
[inaudible]
All right, we are going to ask everyone to take a seat so we can keep going here. Thanks so much. Well, we have We keep adapting. Keep adapting, okay? Technology. We will acknowledge for a moment that there is some cool things happening in the world, other enlightened things happening in the world, like maybe the biggest IPO in history and AI. We have used AI thoughtfully to help build this presentation. We use it all the time, but I just want to remind everyone, treating the body is still a very direct thing, and actually running trials and clinical research is all about humans engaging humans, all right? AI will be powerful, but technology sometimes is your friend. Today, it has not been our friend, okay? We are going to get back to our program.
I am excited to kick off our deeper dive into atrioventricular interval modulation therapy, and we are going to talk about the unmet needs associated with our target patient population in hypertension. I am going to put this slide up for my dear friend, John Salveson, because John got us thinking about the idea that hypertension is the trunk of the tree, and this is a baobab tree of hypertension. It is the trunk of the tree of all cardiovascular disease. When we think about the problem with high blood pressure, and particularly the population that we are targeting, older comorbid patients, we have to realize that just living life feeds high blood pressure, which feeds everything having to do with cardiovascular disease, from heart attack to stroke to coronary artery disease to the development of heart failure, all the way to impairment of your eyes and your kidneys.
This is really the number one problem in the world in terms of healthcare, because it affects over 1.4 billion patients. It is a difficult condition to manage, because it is ultimately not just a lifestyle disease, but it is a maladaptive part of us living longer. Unfortunately, we all have to look forward to the challenges with managing blood pressure, and it contributes to a lot of morbidity and a lot of mortality. This is particularly true when we think about the launch population for the therapy that Vivek and Marat are going to give you further insights into. When you think about the context of our partnership with Medtronic, because the launch population here is patients that already need the device whereby we can deliver our therapy.
In that patient population, for 1 million patients worldwide are going to get a pacemaker this year and next year that also have hypertension. They are older. We are going to dive into that population. They have comorbidities. Once again, they already need the intervention. Our partner, our amazing partner, Medtronic, is the dominant global leader. That did not happen by accident. Earl Bakken founded Medtronic around this technology. The idea that the data we will see shortly, that the submission that is going to be made shortly thereafter is going to then be done by Medtronic, and we will talk more about how this is already built on a new platform device. It is not simple, but we are working hard to bring this to fruition with our partners. It is quite exciting. It is also exciting when we think about where we can go next.
Our vision is to bring this therapy and that technology not just to the pacemaker population, but to patients that really are a lot like, pretty much the same profile from an age, comorbidity, and health standpoint, but they do not yet need a pacemaker. We have a Breakthrough Device Designation for both the first population and the second population. It is really important when you think about the mechanism, the data that we are going to go through, to realize that it tells a story not just about how to help patients that need a pacemaker, but potentially how to help patients that can get that device to benefit from AVIM therapy. We are doing a lot of work with Medtronic. We are doing work on our own to dig into and learn more about how physicians feel about that expansion opportunity, how patients feel about that.
While that work's unfolding, I wanted to share one insight that we thought was pretty powerful, which is we went with a third-party group to a group of these patients that are older, patients that have significant uncontrolled hypertension that isn't well managed with meds, patients that have had prior MI, prior stroke, and asked them would they be interested to get an implanted device to benefit from this therapy. We don't have the pivotal data yet. We were struck by the fact that 70% of those patients, it's a small sample, 64, but that's actually significant, you can get some statistics out of that, said they were willing. We are excited about the broader opportunity. With that, I'm even more excited to introduce, and I'm going to get to introduce both Dr. Vivek Reddy and Dr. Marat Fudim.
It's important that we have, I think, one of the most prominent, influential electrophysiologists here with us. Vivek has been instrumental to the development of cutting-edge technology, pulsed field ablation, left atrial appendage closure, but device technology, both transvenous and leadless pacemakers and conduction system pacing. He is the Executive Chairman of our steering committee. He's been advisor to the company. I'm excited to introduce him, but also after him, Dr. Marat Fudim. Importantly, in Marat, we have a leading heart failure expert and a physician who brings together clinical cardiology, translational medicine, and insights into how we better treat heart failure, both heart failure with reserve, but more importantly and relevant, heart failure with preserved ejection fraction. It is exciting to have both of these guys here because more than anything else, they are almost everywhere. They are at TCT, they're at HRS.
They are highly sought after by small companies like us and equally by big companies like Medtronic, because they can bring together thoughts on new therapy and how that can be translated through clinical trials to use in patients. I'm going to hand it to you, Vivek. Thanks so much, and we'll come back together for a similar discussion and then Q&A.
Okay, thank you. Let's see if this works. Oh yeah, it's not working here.
You can do both.
Yeah, I'll do both. Okay. My charge is to discuss AVIM therapy, and try to, I guess, explain to you why I'm so enthusiastic about it. I think this is going to be a major new therapy that's going to be benefiting, as you've already heard, a potentially very large population. If you look at traditional pacing, and one of the interesting aspects of this technology is it's not a new device. We're not talking about a new widget here. It's actually fundamentally just a new way of pacing through existing pacemakers. I think that's very exciting, obviously, in terms of implementation and clinical practice, it'll be relatively seamless. You know about pacemakers.
There's traditional pacemakers, as you see here, from the very first electronic pacemaker to, let's say, the ones we're using today, both the conventional pacemaker with regular leads, as well as the leadless pacemakers, which potentially could even supercharge this therapy. We may talk about that later. Concurrent with this, there's also been advances in conduction system pacing, and that's probably relevant for us. I don't know if we want to spend too much time talking about it. One of the interesting aspects of AVIM therapy is the fact that we will be forcing pacing in these patients who don't otherwise necessarily need pacing, because that's how you implement the therapy. You've probably heard, if you pay any attention to pacing, that forcing ventricular pacing may not be a good thing. Well, it turns out it's perfectly reasonable if you can do conduction system pacing.
As you'll see, this therapy, AVIM, is completely compatible with both regular ventricular pacing as well as conduction system pacing. Let's talk about the whole program. This started a little over a decade ago. There was the initial feasibility study, first the preclinical study, and then the first-in-human study, which was a single-arm trial. We're not going to spend too much time on it. You can see that even in a non-electrophysiology, in an interventional cardiology meeting, it won the best abstract award. That's pretty remarkable, actually, for a pacemaker to win the award there. The MODERATO II trial was conducted. This was a pilot trial, but it was a randomized trial. It was sham-controlled. We have the data, and we should look at that, because I think that that's going to likely inform what the pivotal trial is going to look like.
We have the initial data, we have the two-year results, and we have additional data beyond that. Then, as you've already heard from David Hochman, there was a strategic collaboration with Medtronic, and I don't know, maybe we'll be talking more about that in discussion. Finally, the BACKBEAT pivotal trial. The trial is, I'm sure you've already heard, it commenced a couple years ago, two years ago. It just finished enrolling for the primary endpoint. We expect the readout to be early next year, and the data will be presented likely in the second quarter of next year. So, what is this therapy? It's basically pacing in an unusual way to drop the blood pressure. Instead of having the normal timing of the atrium contracting, the ventricle contracting, it paces the ventricle early, before you have complete filling of the heart.
What that does is drops the blood pressure. Now, in and of itself, that's not terribly interesting, nor is it necessarily desirable, because normally what the body would do when it sees a drop in blood pressure like that would be to constrict the vessels down, increase the resistance, and that's a bad thing. What's sort of remarkable about this therapy is, you have some long delays, or sort of normal delays, between the atrium and the ventricle, they're interspersed between these short delays. That sort of tricks the baroreceptors, which are the receptors that would otherwise cause this peripheral vasoconstriction. You don't have that vasoconstriction. So what you end up ultimately having is a pacing therapy that drops the blood pressure without some of the adverse sort of consequences, like increase in peripheral resistance. That drops the blood pressure. It's an effect that's immediate.
It happens right as soon as you turn on the therapy. It's not something that'll happen in some time in the future. So it's a very immediate effect, and it's a sustained effect. Let's take a look at some of the data. So, this was the MODERATO II trial. This was the pilot trial that was conducted almost a decade ago, a little less than a decade ago. It was a randomized sham control trial, so patients were blinded to their treatment assignment. It took 47 patients. The trial was conducted in 13 European sites. The patients basically were patients who had an indication for pacemaking therapy, and who also had hypertension and had elevated blood pressure despite being on at least one blood pressure medication, as you see up there. Oh, do I have a No, I don't have that.
These patients were randomized one-to-one to either usual therapy, meaning they got the pacemaker and they were receiving their normal blood pressure medications, or all of that plus the pacing turned on. Again, patients are blinded to the arm that they're in. There was an efficacy endpoint, which is, of course, the change in blood pressure, and the primary endpoint was at six months. The safety endpoint to assess for any safety events. In addition, at the six-month time point, all the patients were crossed over to receive the therapy, and we have data out now, actually past two years, almost four years, and I'm going to show you some of that data. So, here's what you see. On the far left, you see a very important point, which is an immediate drop in blood pressure, as you see a 13-point drop in blood pressure.
And probably one of the most interesting aspects is this, 97% responder. It means basically pretty much everyone has a response. A response is defined by an immediate at least 5 millimeter drop in blood pressure. Then if you look at the ambulatory blood pressure over the first day, again, a 14 millimeter drop, which is pretty dramatic, and compare that, by the way, to the control, sham control, which is basically no significant difference. Then the primary endpoint at six months, you see substantial differences in blood pressure, a drop of over 10 points, both with ambulatory blood pressure and office blood pressure, with relatively minimal difference in the sham control group. And this is pretty dramatic. I mean, I don't know if you're used to looking at hypertension trials.
When you look at, let's say, new hypertension drug trials, if you see a 4 or 5 point drop, that is a dramatic drop. Because remember, these are average numbers in patients who are very well controlled typically. And so this is actually a very impressive drop. Just to give you a perspective, a 10 millimeter drop in blood pressure decreases stroke by somewhere between 25%-30%. That, by the way, is about the same decrease in stroke rate that we see with catheter ablation, atrial fibrillation. So, these are not trivial differences. The other interesting point is, you look at the 24 months. So these are all the patients crossed over who were in the control group. And so we follow these patients out for 24 months, and you see a sustained reduction in blood pressure, about 17 points.
Then on the safety side, there were no important safety events, as you see. Did we go too far? No, this is good. So this shows you the 24-hour blood pressure. So what you see here on the far left and the far right is during sleep. You can see the times here. And that's the normal variation. So in the gray bar, that's the control group. You see the blood pressure rises a little bit as the patients wake up, and then when you go to bed, the blood pressure drops. That's sort of normal. Notice that in the treatment group, there's a substantial decrease, okay? And the decrease is both during the daytime and nighttime, which is what you want to see. Now, the other interesting study that was done is this one. This was the reversible, or what happens if you withdraw the therapy.
There'll be times in the patients' lives when you don't necessarily want their blood pressure to be lower, right? Let's say they're undergoing surgery or something else. And in those situations, the question is, what happens if you stop the therapy? Is there going to be rebound hypertension? Then if you turn it back on, what'll happen? And this is what happens. So you can see here on the far left, those are the orange bar. That's the blood pressure in those patients, and this is about four years out, practically. And you can see, again, the 122 is about what they had. Oh, I read this wrong. Sorry. The 122 blood pressure is in the group at six months. Four years out, if you look at those patients, that's the day zero. Again, it's basically the same thing, 122, okay? But then look what happens.
If you turn off the therapy, the blood pressure goes back up to 133. So it goes back up. It does not go up higher. It goes back up to what it was before the patients received the therapy, okay? Then seven days later, you turn the therapy back on, and the pressure drops back again to 124. I mean, in fact, this is actually even better than medications. With medications, you can stop them also and then start them up again. But the effect does not go away like this, right? It takes some time for the medication effect to go away. This happens immediately. Okay. So, that brings us to the current trial, the BACKBEAT global pivotal trial. This is also a double-blind randomized trial, or is a double-blind randomized trial, conducted at 92 sites in 15 countries. About half the patients were enrolled in the U.S.
The total number of the patients, you see, it is close to 350 patients were randomized. The study is well-powered, arguably too well-powered, 95% statistical power, both on safety and effectiveness. This is based on 284 evaluable randomized patients. So, this is a study where, again, looking at patients who had uncontrolled hypertension, who were taking at least one and up to three antihypertensive drugs, and they were patients, again, who had a bradycardia indication. So, these are patients who either just received a pacemaker or are about to receive a pacemaker. Once they decided to participate in the trial, the software was downloaded onto the device, and then they were randomized one-to-one to either the treatment in orange or the sham control, which is the medical therapy.
The primary endpoint, which is going to, again, read out early next year, is the between-group difference and change in ambulatory blood pressure at three months, so the 24-hour ambulatory blood pressure at three months. Then there is also safety endpoints. So, there are two important safety endpoints. There is the early one, which is, again, looking at three months, looking for unanticipated safety events. Then these patients are going to be followed out to one year, and that is going to be really important. The patients, by the way, are going to remain blinded out to 12 months. So, they will be in their respective arms out to 12 months, and that is really important because we will look for clinical events. For example, will we be able to decrease the amount of atrial fibrillation? Will we see changes in left ventricular remodeling? Will we see changes in atrial size?
Will we see even changes in clinical events like stroke, et cetera? This is a reasonably sized study, so we may have hints of these phenomena. Okay. The trial, again, it is a very large trial. It is basically taking anyone who has a pacemaker indication, sick sinus, AV block, all the usual expectations, expected patients. The patients are going to be older. That is what we expect. This is a pacemaker population. They are going to have comorbidities. Again, they will have diabetes, coronary disease. Some of the patients will have previous stroke or infarct. We do not expect to have a large number of AFib patients. In fact, the trial excluded patients who have permanent or chronic atrial fibrillation. They could have paroxysmal AFib, but not chronic AFib. Also important, let me go back.
Also important, as we said, the AVIM therapy can be activated soon after implant, or it could even be activated in patients who had a device implanted a couple years ago. Yeah. So, in terms of the workflow, I mean, one of the nice things about this is, as I said in the beginning, this is not a new device. There's no new widget. It's really just turning on the therapy on the pacemaker. Electrophysiologists are used to following these patients, and cardiologists are used to following pacemaker patients. They come in every X number of months. We check out the device. We check out whatever other, let's say, other therapies may be on the device, heart failure therapies, et cetera. So, I think in terms of workflow, I don't really see any particular problem. Finally, I just want to end with this slide.
One is the point that David brought up in the end of his presentation, which is that while the trial is really directed at bradycardia-indicated patients, so patients who need a pacemaker for bradycardia, the FDA actually gave a label. Well, the label hasn't been given yet, but basically, we're expecting that the label will actually also include patients who don't necessarily have a bradycardia indication. Now, why would a patient necessarily receive a pacemaker just for hypertension? Well, I think we've already heard. I mean, I think the market research that David talked about was very interesting. I think high-risk patients, it's very possible they'll want, they'll be willing and interested in having a pacemaker even if they don't have bradycardia indication.
We're also going to hear from Marat, I think, in just a few minutes, of some of the structural changes that we're seeing with AVIM therapy. I think when you put that into the full context, I think it's very likely that this therapy is going to be used for not just the bradycardia patients. I think that's going to be particularly true with this. Let's see, where is it? Yeah. With patients who, in the future, hopefully, there's a leadless pacemaker therapy that's being developed by Medtronic, a single device that can pace and sense the top chamber and the bottom chamber. Again, this hasn't yet been used in patients. This is part of a development process, and hopefully in the next year or so, we'll start hearing about first-in-human data.
But you can imagine a therapy like that coupled with this AVIM therapy, suddenly you have a very simple device that could potentially be used for hypertension treatment, period, unrelated to brady pacing. With that, I think I'm going to go ahead and stop. Yep, I'm going to go ahead and stop. Thank you, and I think we'll have time for questions later.
All right. Awesome. Thank you so much. I guess it comes on and off, huh? Hello, everybody. My name is Marat Fudim. I'm a heart failure cardiologist. My introduction was a lot shorter than that of Vivek Reddy, which I do not appreciate. I traveled all the way from North Carolina. All right, so what I will be talking about, though, is going to be an extension to what antihypertensive treatment really can achieve when you consider hypertension as probably the biggest killer in the space of cardiovascular disease. It's the silent killer, that's how we often refer to hypertension. You see here. So, hypertension tends to be one of the key precursors to the development of conditions such as heart failure, which affects around 7 million people in the U.S.
The majority of heart failure in the U.S. is now driven by a condition we would call heart failure with preserved ejection fraction. What happens is that if you, as a heart, have to pound and pound and pound to generate a high pressure, 140, 150, 160s, every day, all day, every day, the heart starts to become thickened, then it starts to dilate in the top chambers, and we refer to that as diastolic dysfunction. It's really a surrogate of how pliable is the heart and its ability to move and relax, accept the inflow of blood, and eject the blood. Now, why would you care about heart failure and hypertension being the main precursor to it? Well, heart failure is sort of the bane of our existence. 7 million, as I indicated, it's the number one cause of hospitalization in the U.S.
There's only one disease state that's more commonly coded in hospitals than heart failure in the U.S. today. Any suggestions? What's coded more commonly as an ICD-10 code? ICD-10 code is how we code things. Childbirth. Now, I don't consider childbirth to be a disease state. Having had to get my kids ready early this morning in North Carolina for breakfast, it is a disease state. Someday. This is not recorded, right? My wife cannot see that material. The reality is that because hypertension is so prevalent and it's silent, we of course have been treating it for years and years, but control of blood pressure is actually terrible. I don't know how much you know about it, but around 50% of all hypertension in the U.S. is actually not considered to be treated.
It is treated and controlled is with the cost of many blood pressure medications, and people in this room, probably to some degree, are on those medications itself. There's the 50%. If you do the math, around 1.4 million patients that actually have heart failure have still underlying uncontrolled blood pressure, and that being one of the key drivers of the disease. Now, there's a lot of microvascular changes that occur as well when you have high blood pressure for a while. The heart becomes actually fibrotic, and that process takes a couple years. Nobody says that uncontrolled blood pressure in your 30s and 40s will lead to heart failure right away. It does probably take a decade or two for you to start developing structural changes.
But the reverse tends to go a little faster, because if you unload the heart and let it, quote, unquote, "breathe easier," you will start seeing changes relatively quickly. I will show you some of that data here later. Now, I will not show you how great this device is in lowering blood pressure. That was the prior talk. What I will tell you is where you should think beyond blood pressure once this is on the market. That is actually how I got involved in the company. I was not part of the hypertension program, but realizing that there might have been some benefit to it. The company has thought about the benefits on the performance of the heart as it might relate to heart failure for a while.
And so this was a study of 16 patients where they took the standard uncontrolled hypertensive population, gave them an implantable device. These patients obviously had some pacing indication. What they have done, they have done a PV loop study. A PV loop, just to give an idea, it is a dedicated catheter you float either into the right ventricle or the left ventricle, and it measures pressures and volume at the same time. In the sphere of the coolest things you can do in cardiovascular medicine, that is as detailed of a physiological assessment as you can do. These catheters are also not cheap. But what it does, it measures volume on the X-axis and the pressure on the Y-axis. And you see multiple lines because what they do is they record multiple heartbeats. You are not allowed to just record, say, one heartbeat.
They are recording usually 10, 20 of the heartbeats, and then they average them out. Okay. So what they did then is they started pacing either in a typical RV approach or in a physiological approach on the right side there. And what they found is that the orange is what happens when you pace, and it moves to the left and down. When your PV loops move to the left and down, it means the ventricle is becoming smaller and the pressures, systolic and diastolic, are coming down. Okay? So you have a drop in pressures. That is what you have seen in prior talks, but it also brings down the volume. And it was even equal, if not more dramatic, when they did the more physiological pacing, think of His bundle pacing and those alike. So that was quite impressive.
And so if you actually do the math, and I will show you some of those details, not only was there a decrease in diastolic and systolic volume, there was a decrease in systolic blood pressures, diastolic blood pressure, which equals wedge pressure. Left ventricle end diastolic pressure is that value, came down. Now, it started in a normal zone because these patients did not have known heart failure. So it started in the teens and dropped even further, but it also reduced total peripheral resistance without significant change in stroke volume. Having said that, stroke work came down, and this is actually the total area in the circles that came down. So the heart was able to perform at a lower pressure, at a lower volume, and that is important for the heart because it does not like to generate too much work.
It did all of that work at a lower workload, which we call stroke work. This is actually now the summary of the individual observed changes. These are two different pacing modalities that were performed, and it reduced the pressure similar to what you have seen, but this is now all acute right then and there on the table, 17 and 19 millimeter. If you now look at the volumes, the volumes dropped 12 to 18 milliliters on the diastolic volume. On the systolic volume was 11 to 14. Those values are a little bit smaller because the heart actually squeezed in the meantime and just ejected around 70 cc, so you would expect those values to be lower. But most importantly, it actually also reduced the diastolic pressure. That is that bottom right corner. There was a drop of 2 millimeter Hg.
It does not sound like a lot, but it actually is because you started off around 10, 11, 12. That was the value where they started. So a drop of 2 points is actually quite significant. That is diastolic pressure. That is the stroke work I was referring to. The units are not as meaningful here because that is the total area within the PV loop area, so there was less stroke work performed without significant change in stroke volume. That is the one question always comes up, what actually happens to the cardiac output, stroke volume, and it actually does not change significantly. Things that we perform on PV loops, if I can go back. I hate to bombard you with this physiology. It might be boring or not. We actually plot curves based on the repeat performance of the curves, and we call them the elasticity.
We actually measure the elasticity of the heart by plotting curves this way and this way, and repeat it over every heartbeat. Then when we summarize them, we get these values that tell us what the contractility and the elastance of the vasculature is. You can see that the elastance of the heart and its interaction with the heart was reduced, so it was easier for the heart to eject blood into a more elastic periphery, and the contractility speaks directly to the contractility of the heart, and that actually did not change. This therapy does not actually directly change the contractility performance of the heart. The muscle does not suddenly get stronger. It is really that we are playing with the loading conditions, so the preload and the afterload of the heart, rather than change directly then and there the inotropy of the heart.
That experiment got repeated now in a different patient population. That is the MODERATO II population that Dr. Reddy just talked about. But now no catheter was implanted. It was not a PV loop catheter. Now they have done a single beat method where they looked actually just at the blood pressure together with the echo variables, and they demonstrated very similar curves to patients that did not have the therapy on for the first six months. You see that the curve shifted not to the left and bottom, it shifted to the right. If you do not do anything, these patients have uncontrolled hypertension, they actually get worse. The ventricle started dilating, and the pressure was rising, and you had actually a reverse of that therapy in the subsequent six months in those patients where it was turned back on.
Repeatedly, this is a slightly different method, but the concept of the PV loops was comparable here. That has actually been repeated now a couple other times in other data sets. What I am going to show you now is where I actually started to get involved with the company. That became quite interesting because when they started looking into their MODERATO data, that showed all this beautiful data on blood pressure lowering, I approached the company, I said, "Well, this is kind of interesting because when I looked at the different characteristics, uncontrolled hypertensive patients in their 50s and 60s, they have a little bit of AFib, they are pacemaker-dependent.
If I see those patients in my clinic, well, I call them heart failure patients." The company told me, "Well, but they were not allowed to have symptoms, and they were excluding patients with frank heart failure." The problem is, if you ask the patient, "Are you asymptomatic?" Think of your spouses or elderly parents, they will say, "Everything is fine." The reality is that patients often with heart failure actually do not admit to the symptoms. The reality is that many of them might have actually had latent or subtle signs of heart failure, which we refer as diastolic dysfunction. What I asked the company is, "Why do not you disclose all the data to me? I am blind to it. I do not know who had therapy, who does not.
We are going to review all these patients' charts and re-review the echoes to see how many of them had actually clear evidence of diastolic dysfunction, and what changes if we now pace these patients longitudinally? Do we have an effect beyond blood pressure alone?" First of all, some might have been surprised, others not as surprised, but 60% of patients that were getting this therapy at baseline already had diastolic dysfunction. They had clear evidence of destruction of the actual heart muscle, whether it is a dilation of the atrium or being so stiff that they met criteria of poor relaxation. In order to enter the trial, I could not have told the doctor that they are symptomatic. I am telling you, some of them probably were clearly, frankly symptomatic, but that is how trials work. You exclude as good as you can.
Then what we did is we now assessed these echoes serially. Some of them got the therapy, some of them do not. I had no insight into who got what. In a blinded fashion, this was all reviewed, like a core lab would be doing this. What we noticed, and one of the key metrics of diastolic function is something called e′. Okay, so I am going to tell you what e′ is. When the heart constricts, it has actually two functions. It squeezes like this to squeeze the blood out, but it also works like a piston. The piston function is actually more important. That is the descent of the heart, like in a car engine. It descends and relaxes. That relaxation is called e′, and it is very, very important.
The first thing you lose as a heart failure patient is the ability to relax your heart and, like a spring, to rebound. That is measured by e′. If you go up in a treatment arm, that is quite reassuring. That actually increase is quite significant, and that was not seen in the control arm. E over e′, which didn't seem to change in the follow-up, is another metric, but it's loading dependent. E over e′ is also piston function. That's the e′, that's the second component. The E component was that the serum pressures had to be elevated for you to be able to exactly change. These patients, remember, were not congested heart failure patients.
They might have had heart failure, but it was sort of undisclosed and subtle, so we wouldn't have expected that the E over e′ would be significantly different. You seeing this? Perfect. Let me go back. I'm not sure that I missed a slide. Yeah, perfect. What I hopefully demonstrated to you is that hypertension is a key contributor, silent killer. It's the most commonly prevalent cardiovascular disease in the U.S., period. Also, of course, globally. It is only surpassed here by heart failure as the most deadly disease that it will eventually lead to. You'll see all the data around it being a device-based therapy to treat hypertension. I will tell you, I am involved in the hypertension space.
I help lead our hypertension clinic on top of our heart failure with preserved ejection fraction clinic, and I'll tell you that amongst the therapies that we have, like renal denervation, we actually tested things like splanchnic nerve denervation in our clinic, drugs that are coming to the market. None of them has an immediate effect like this therapy. That's one big benefit, the therapeutic confirmation of technical success right then and there. We were just sitting in the office reviewing some of the data. That is one of the key advantages, that you see the effect, and the effect is in a magnitude much larger than many other therapies we typically see. The key part is also it's on 24/7. If you actually go to patients and ask them, "Are you taking your medications?" "Of course. Yes, Doctor, I take my medication.
Yes, I also floss my teeth every time," to another way. When you actually check their urine, in clinical trials, we check a patient's urine. We have trust issues. That's the German in me. We don't trust people. We check the urine in clinical trials, and what we find, around 50% of patients don't have drugs that are detectable, or the drugs that they promised us they would take would be not detectable in clinical trials. These are patients signing up for a clinical trial, and they're lying in our faces, okay? The beauty of device-based therapy is that it's always on. You do not have to rely on a patient's intake, which has, for 100 reasons, there's, of course, issues with compliance. It has favorable hemodynamics. You can obviously, hopefully, follow my rationale.
If you are always reducing the blood pressure by, let's say, 15-20 millimeter Hg all day, every day, that's going to accumulate over the months and years this therapy is going to be in. I just showed you six-month data where there's already favorable changes in patients that were not symptomatic with clear evidence of diastolic dysfunction. You can imagine that it will accumulate in a properly powered clinical study. This will result in improvement in clinical outcomes, such as heart failure, heart failure-related hospitalization, and we address what is our biggest need. To the fifth point that Vivek made earlier, of course, we have an infrastructure in place that actually does this. I mean, we refer to electrophysiology all day, every day. EP does not refer, though, very often back to heart failure. We have to talk about that.
I think that was my last slide.
We're going to do a little discussion here. We're going to now get to some of our questions as well, and we're also maybe going to invite Allen and Duane Pinto up, and I might have to be the standing, the man without a chair, depending on how this goes, but I'm happy to do that. Got good legs.
That was kind of weird.
Yeah, I know. Yeah, it's all right, you know. Darren, maybe you will kick us off, and I will start going through some of our questions as well.
Yeah. All right. I think a question that the audience and a lot of people generally want to know is, what would be a good outcome of this trial? What would you consider meaningful, be excited about? What outcome come second quarter next year, and we are standing on a stage excited, what are you going to be happy for? What can you kind of guide us to, and what would be successful? This is AVIM question to start with.
I mean, I think that we can look at efficacy, safety, and let's say, applicability. On the effectiveness side, if we see the kind of drop that we saw in MODERATO II, say a 10-point drop, that would be. If we see a 10-point drop, I think that would be astounding. So, any double-digit drop, I would be extremely happy with. So, that, I would say, is a win. On the safety side, we do not want to see any complications. And again, this is a large trial with 350 patients, so I think it is a well-powered trial to look for safety events. The fact that we did not see anything in MODERATO II obviously makes me very optimistic. But the third one, I think, which is also very important, is the applicability. What percent of the patients will show a response?
And that is why I sort of highlighted that from the initial MODERATO trial, where we saw, what was it, 97% responsiveness. So, yeah, I mean, I think those are the three aspects.
I'll answer that. You got to put things into context. We were very excited, and still are, about things like renal denervation. But renal denervation causes a 5-6 millimeter Hg drop as compared to sham control. I mean, this is going to be a much larger change. I'm just comparing those two because those are the two device-based therapies. I think getting a double-digit drop in your systolic blood pressure is quite meaningful. Again, the idea that it's 24/7, all day, every day.
Sorry, let me add one more thing because I forgot about this. Most of these patients that are isolated systolic hypertension patients, and these are patients that are very difficult to treat, typically, in terms of blood pressure. The fact that the majority of our patients are isolated systolic hypertension, and the fact that we're able to treat them, I think, is really astounding. I'm not sure how well, for example, renal denervation or some of the other therapies would work in this specific population.
Yeah, I mean, I think those are the two things that stress me out about treating hypertension, is I don't know whether it's going to work, the thing that I'm doing, giving them pills or renal denervation. This, you can see if it works. It's not up to the patient, as both of you made the comments, it's not up to the patient whether it works. That's a dramatic benefit. Allen can do the renal denervation. We don't even know when we're done with the procedure yet, and then we also don't know until later whether it really works or not for the 3-5 points of blood pressure. This is amazing.
I'm going to take a question from our app here, because it's, I think, a good relevance to this discussion. For clinicians, I'm jumping around a little bit, I'm trying to get them in the flow. For clinicians, based on what you guys are saying, assuming we see success in the trial from an efficacy standpoint and safety, and it's a commercial therapy, are there any reasons you wouldn't use AVIM Therapy on a pacemaker-indicated patient who is already getting a Medtronic pacemaker? If so, what would the patient criteria history be that would influence that choice?
Let's start with that also are hypertensive despite meds.
Yeah, sure. I don't see a good reason not to. If they have a brady indication-
Why would you not substitute meds?
I'm sorry?
Why would you not substitute meds? Let's say this is approved, right, and it works, and there's a million side effects, patients don't like to take their medications. Why not do this
Right
instead of medications?
This was a study in patients who had not already achieved blood pressure control, but I think your point is well taken. I would not at all be surprised if some patients decide not to take the medications, and I am 100% sure that once the therapy gets approved, people will be doing those kind of studies to actually use this as a substitute. But that's just not how the initial design, the study was designed. But your point is well taken.
So, if we go back to the last couple decades, pacing's a bad thing. Here we are telling people to pace, and here you are getting up and telling people how excited you are about treating hypertension. Dr. Fudim, you're now looking at the actual outcome and the changes in the physiology and the cardiovascular. Was that warranted concern, and how does that data that you're looking at, and if that data reads out positively again, how does that change our whole perception of pacing?
Well, I'll leave the specific answer as to why this pacing, quote unquote, "is safe pacing," but your company has actually done quite a bit of work on safety surveillance longitudinally. That's why ECLIPSE was done. Why would you do ECLIPSE in hypertensive patients? Because there was a theoretical concern of you would actually pacing-induced heart failure. That's one of the concerns we have theoretically around pacing patients all day, every day. But this pacing is slightly different, and that was just A, not seen in your studies to date, that is closely surveilled by the DSMB. But what I demonstrated is actually the reverse is true, because the patients chosen have so much diastolic dysfunction and stiffness in the first place that it's really the hypertension, by treating it, outweighs any potential harms that's seen so far.
You can extrapolate this, that this at some point in the near future could become actually dedicated heart failure therapy, where we, by the way, test in EP, and Rob sits in the first row here, they do a lot of pacing-dedicated heart failure therapies in the space of heart failure.
I saw an anaphylactic reaction from the Medtronic people about pacing is bad. But what I will say is, as a TAVR person also, we have to be a little more circumspect about labeling pacing as bad. There are a couple of class I indications that save people's lives with pacing, and if you have an ancillary benefit, for example, with CRT after a TAVR, that's in aortic regurgitation, that's a big deal. Or if you can get a pacing ICD that shocks you out of death, or if your hypertension is treated better, those are life-saving devices.
I'm going to jump back to some more questions we've got from the app here, because we've got some time for that, and we'll also have some more discussion. We'll work our way back to Virtue as well. One question here related to data as well. Sometimes we see control arms in rigorous, well-run trials for hypertension have better clinical results than expected. What do we expect here? Do we expect also that the AVIM patients in the BACKBEAT trial could do better than the MODERATO II trial? Two questions there that we put to you guys.
Yeah. When you think about hypertension trials, when they're well-done trials, you don't see that kind of fluctuation. See, hypertension does this. If you just follow people over time, this is what hypertension's doing. If you do a trial where you're not carefully assessing the blood pressure, where you don't have a study where, for example, you don't take patients just when they happen to have their blood pressure high, but rather enter the patients, then follow them for a month or so, as we did in this trial, to make sure that their blood pressure's really high. When you do the trial carefully, then actually the control patients tend to behave as you'd expect. That's the reality.
I think that some of the, I guess, the sort of knee-jerk sort of concern from the Symplicity experience, which is where I think this question came from, is really not warranted in this particular-
I would highlight we have a run-in period, which-
Right, there's a run-in period.
We do fully expect to see from initial consent through the run-in period, which may be, it's going to be a minimum of 30 days. There will be blood pressure reductions from
Yeah
when we meet the patient, who may not be compliant at the time of consent, to when we bring them in. We also do, we saw it in MODERATO II, we did see reductions, so we expect that. But I think the other question, is there a chance that we can see better results, was something that was also asked.
I'd like to jump in on here, because one of the people in the room here is one of the co-inventors and founders with us, Yuval Mika, of this therapy. He always says, "This question is for a therapy that doesn't have tremendous benefit." What he's saying is, when you make a big change in blood pressure, you're less worried about the small numbers about what the control group does.
We are seeing very large changes in blood pressure. I would not be surprised, and I would not care if there are small changes in the control group, because the therapy itself overwhelmingly provides benefit. David's second question was, could we see numbers better than MODERATO? We think so. We have worked for 10 years to further development and work with algorithms and work with our partners to learn from what we did in the past to make it better. There is absolutely a potential for us to do better. But the first question was an important question, which is, if we just repeated what we did, would we be happy? Is that a good thing? I think everyone agrees that is a good thing. Anything more than that, it is going to be a party.
But just the second question, I just really want to address that. It is interesting in the data that Marat showed, when you looked at the changes with conduction system pacing versus regular right ventricular pacing, the changes were actually, they seemed more striking with conduction system pacing. So, there is a small reason to think that in this trial, where half the patients are, so we will probably have conduction system pacing, we may actually see a more significant benefit. Again, this is just a hint, so I am really looking forward to seeing whether or not we see a greater benefit in that population.
Sure. There was one more question that came in the app that I want to just address before you go to the next one, David.
Yeah.
The question was, "Well, so could any pacemaker go do this?" The answer is, it really is not. We had to go rerun the software and rebuild it and revalidate in order to program it to do these interchanges and how to go do this. This will launch on a Medtronic platform, which they are going to apply for approval, get an indication, get an approval, and the therapy is only going to be available on the devices that they sell. So, this is not something that somebody can do with an existing program or existing pacemaker. So, while we are leveraging the history of pacemakers, this is particular to the devices that we and Medtronic are going to launch. I just wanted to make sure that question got addressed.
Sure. We have a bunch of questions. I am going to answer a few just because they are quick. We had a question about the 3.7 million patient number for the expansion market. That is a global number. We believe the annual addressable is around 1 million patients in the U.S., and we have looked at that rigorously. Let me just be clear, there is 120 million patients in the United States diagnosed with hypertension, so 1 million patients annually is a fraction of a fraction. There was a question about how many patients have hypertension that get dual-chamber pacemakers. It was lower than our number. I will get you the papers. The most recent paper came out about a year and a half ago. The reference is 85%. I will get you that one. Question for you guys. Three-month primary endpoint results, is that enough to move physicians? If not, what are you looking for?
I think so. In three months, you are going to have the results, and if you see a significant difference, as we saw in MODERATO II, absolutely. Just remember, we will still also have the one-year data. The patients are going to remain blinded to their treatment out to one year, so we will also have that data.
The other question is, the statistics are powered for finding a difference between groups in ambulatory systolic blood pressure of 5 millimeters or greater. The question we had is that going to be viewed as clinically meaningful? There was a follow-up, and I might indulge, if you are willing, Rob. The follow-up question was, let me just make sure I have it here. It was, "Is that enough for Medtronic?" I think was the question. I think, so is it enough for the clinicians, but will that type of difference, if you want to jump in, be meaningful to you guys commercializing the therapy? Yeah, I will give you that.
I will hear it.
He's the only one who gets a mic, by the way.
As I said before, even a 5-millimeter difference, if it's a statistically significant difference, that's what you see with most new antihypertensive drugs. I think the answer is yes, particularly when you're talking about-
By the way, not ambulatory. You tend to only see that in office.
Yeah, that's true. But particularly when you're talking about basically turning on a therapy. We're not talking about a new procedure in this patient. We're literally just flipping a switch.
Can we get this mic on?
I'll stand for a second. For those who don't know me, Rob Kowal, I run the pacing business at Medtronic, and I was a clinician years ago. I've recovered from that already. No, I would say that really, I'm fully aligned with what Vivek says, not to extend the repetition too much. This way? Okay, sorry. I don't want to block them. 5 millimeters is clinically significant. What we care about is what's clinically significant for a patient that's going to lead to a better outcome. There's a wealth of data about how you can kind of look at the benefits from a cardiovascular stroke standpoint by how much you lower, and five is meaningful. I think the secondary point, which is actually critically important, these patients are already getting the pacemaker for another reason.
You're not putting them at any incremental risk unless we find something in the trial that this therapy on top of the pacing creates risk. I think we'll be examining that, but we're very confident that that's not going to be the case. Again, you're not asking someone to undergo a new procedure, a new expense related to getting the additional therapy, and that's what's a critical component of this for us.
Thank you, Rob. You want to change gears a little bit here?
Mm-hmm. There was a couple of Virtue-like questions that came in. One of them was like, "Can you tell us about how this product's made and manufacturing and stability?" Nice commercial kind of questions. The beautiful part about Virtue is you make a pharmaceutical agent that's a lyophilized product in a vial and a drug, and you use standard techniques to go do that drug, and you make a device. The device can have two to three year shelf life and be stable. The same vial of drug can be used across all the different codes and sizes, and this creates a lot of flexibility for a hospital where you don't have to have drugs sitting on the shelf with short shelf life. We continue to produce this and learn and grow and make our manufacturing at scale much better, and our stability is growing every day.
We continue to provide the agency updates on a routine basis as we get more stability data, and it's growing. It is a very unique product in the sense of you make a drug on one hand and you make a device on the other, both well-known, both completely different. You don't have to live in a world where you have to get the drug to interact with the device and make a shelf life together. We can keep them separate. So it's a unique program from that perspective. Another question came in, and I'll address it to you guys. Hey, you're running a non-inferiority trial, and you feel confident there's going to be superiority, you hope there's going to be superiority. What would be a meaningful difference in the separation in these lines that could drive your decision-making beyond statistical power?
That's a great question, actually. It's always the question. You can make the sample size endlessly large and then have a statistically significant difference between two therapies, but it's not clinically meaningful, and I think this is what this question is. I would say this. Right now, based on the current therapies we have and the data we have, the one-year event rate of target vessel failure is about 16% or so, but you saw the three-year data is at 35%. So, if you get the three-year data to be around 15% or 20%, I think that would be a pretty dramatic difference.
I don't know. It's difficult for me to answer that because it's not a numbers answer. It's a qualitative answer. I could give you a stats answer of what, in a non-inferiority trial, subsequent superiority testing and P-values and stuff like that of whether it would be compelling to me as a clinician. But to me, numerically better in something that, where the curves start to diverge, I would assume they would continue to diverge, and I'd want to see the data. But early, if there is a superiority signal, whether it's P-value or not, and it's numerically in the favor, all the science lines up that this should be. It's built on a foundation, not a statistical modeling foundation. So, the science lines up, the first primary outcomes, that is enough for me to switch because there's not going to be a safety issue.
I think everybody in the audience would say, "Well, wouldn't I want the thing that's better?" Then let the stats play out for three years, as Allen said.
Just to reiterate, because I. A numerical difference at 12 months is part of what you're talking about doing, which would get your attention. I guess what you're saying, Allen, just want to make sure I understand, is the numerical difference at 12 months could translate into a widening difference over longer time frames, particularly given the long-term data that we're seeing from drug-coated balloons.
I think that the one-year data is not so bad, so to speak. More than 80% of patients at one year are fine, but then when you start following them out, I think the data is somewhat disappointing with the current technology. You say more than a third of patients coming back, right? I would say if you can meaningfully reduce that number, I think it would be a win. You also have to kind of think about, I don't want to go into all of these details, but it's not so simple depending on what size stent is it, how long of a stent is it? Is it a side branch or a main branch? Are we talking de novo disease or stent failure? All these numbers are different, right?
The expectation in terms of long-term outcome is different for these subpopulations as well.
I will just answer for the company for a minute, which is there is a question about why do a non-inferiority trial rather than superiority. Some of that comes down to resources and time. Optimizing for statistical superiority requires you to go larger. That said, the signals I think that we see, we think gives us a shot. This point is really important, which is you have three different outcomes. You have non-inferiority, you have non-inferiority with numerical separation, with directionality that could be significant, and then you have superiority. So, obviously, we prefer the latter two, but we think we are well set up. I think there was a question that maybe
Just-
Yeah, go ahead.
The sample size and trial design was really based on AGENT and AGENT's performance as well as our prior performance. If we meet our intent to treat and they meet their past performance, you are very close to being statistically significant. If we get any closer to our protocol compared to what we did before, we will. So this is a trial that is designed for non-inferiority, but if we can perform like we expect in the prior trial looks like, there is a real potential that you have a separation, and there is a real chance that you can get statistical. Again, you are comparing paclitaxel sirolimus. We know sirolimus is one, and you are dosing at higher levels for longer. There is reason to believe that this could be significant.
Question on the pivotal analysis designed to assess Virtue results in one or two-layer stents. Maybe we could just comment on how we designed the trial, and maybe ask a question if there is any expectation that maybe a difference of effect for Virtue versus drug-coated balloons in two layers of stents.
I think two layers of stent pose another level of problem, which is the mechanical issue of having two layers of stent with recurrent in-stent restenosis. Obviously, one hopes that having more potent and higher concentration of sirolimus will help. I think a lot of it is about the prep. In this trial, it is limited to 30%, so we cannot go over 30% of double layer or multi-layer stents. 70% will be single layers. It is really difficult to predict, honestly, how it is going to shake out. We know that those patients do very, very poorly. To be honest with you, the bar is not very high.
I mean, the reason it is stratified is because they are different patients, they are different populations, and you want to see if the treatment effect is different in those populations. There is a little bit of a trite saying that, "Give a therapy that works, the higher the risk that the individual, the more you have to shine." That may not apply to double-layer stents, because in those cases, you may be destined to fail. So, what you want to know from a scientific standpoint is the two different populations, how is Virtue performing? If there is any shot on goal that is going to work, it is going to be Virtue.
A couple questions on just follow-up on mechanism. I think we have talked a lot about mechanism of action for Virtue in terms of delivery. Maybe I will ask you, Darren, the question here has to do with the IP associated with Virtue, and maybe that as it relates to the mechanism. I am paraphrasing the question, I apologize, but I think I got to the gist of it.
Yeah, so this is a interesting question. We spend as developers and engineers, as company creators, so focused on IP. Across the company, we have, I think, four or five people that have 100 or more patents in their own fields. So we have a lot of innovation in this company. There was a conscious decision when we started working on this pharmaceutical agent not to file IP and keep it trade secret. The timeline that goes for the development of a drug is hard. What we have created in the new particle system and how it is manufactured and how it is tested and how it is evaluated, we have not disclosed and it is trade secret. That being said, the interface and the interaction with the AngioInfusion Balloon is patented, and it is the interface of how these work together is patented, and those patents continue to be forthcoming.
We are actively working on the next generations of these infusion-type devices for different applications and other enhancements in our current. That continues to be filed as patents. I think as hindsight's beautiful, I think the choice not to file patents was a really good one. We are now on our 16th or 17th year working on this. For those of you who know patents, that's a long time, and that becomes prior art, and that becomes something that other people can take off from. Nobody knows really how we have developed this and built this, and it's a significant thing to say because big pharma hasn't developed a long-acting sirolimus. This was a very wise choice of ours to not disclose.
To shift back, Vivek, would you expect you or the Mount Sinai practice or other practices to move your implant volume from one vendor to another vendor based on the availability of AVIM Therapy?
I mean, I think we are going to have to, because once the cardiologists know about this, which they will pretty quickly, assuming a positive trial, et cetera, they are going to want the device. The patients will want it too. There are very few things in pacemakers or devices that actually capture people's imagination. For example, when pacemakers became MRI-compatible, that was a big deal. If you weren't MRI-compatible, you could not implant the pacemaker. That happened very quickly. I think this is going to be another one like that. Unless there's some other compelling reason, I can't think of one right now, I think we are going to be sort of forced to implant.
Yeah, it's a quite competitive market. It's quite a competitive market to go beyond the pacing standard across all pacemakers. That's what they do. They've been developing for years and decades. That feature is actually something very important also to referring providers. We do that for the high-voltage devices where features of the high-voltage devices, such as having good remote monitoring, having not good remote monitoring, is as little as that already turns us to wanting one device over the other. I think this will be a far greater incremental factor to consider when referring for pacemaker than battery longevity, 7.5 versus eight years. These are minor details as compared to, "Oh, this also treats your blood pressure by 15 points." That is a big, big, big deal.
There was a question about that, and that half a year is about, is exactly roughly the worst-case scenario on battery.
I just I want to make a non-proprietary comment. Why use a pacemaker, right? It's a boring product, so I've been told. I don't find them quite as boring as everyone on the stage, but it's a scaling factor, right? It's been around for years. It's a different device, but it's the exact same procedure. It's the same box. We know how to manufacture them. We know how to do it with a quality level that is understood and accepted, and there's numerous people who know how to implant. If you want to take a therapy and scale it quickly, use a pacemaker. If you want to do it slowly, pick a procedure with a new product that has to train, and then there's an unknown safety profile and all these other things.
I think the beauty of using a pacemaker and the reason why we engaged in this is that not the unknowns, but all the knowns. When you look at all the knowns and the ability to scale quickly, that's what healthcare systems want to see, the ability to take a new advance and scale it. That's how we think about things as well. I just wanted to say that.
I think I'm going to leave the stage now.
Well, I think we're almost done. Who wants a little more? Because no one seems antsy, but we do have cocktails. I think we could just get one or two more questions in. This one was interesting, and we're not going to get to all them, and I really appreciate the questions. Just focusing just back on Marat's presentation, we got a question, "Will we get any data on the possible improvement in heart failure in patients included in the BACKBEAT trial?" It would be interesting to talk about the echo data in context. We have echoes, but maybe we just talk about what's in the trial and what might be
I mean, Vivek would be probably better suited, but that was an active issue to be considered when the trial was designed, is to capture the echoes when they're done to look at. By the way, every time you do an echo, you don't only look for safety purposes, but you actually capture the diastolic component, and then, of course, capturing events. I mean, in the perfect world, and I think that is, there's a good chance it will occur, when you follow up, you might have actually few events. These are high-risk patients that I just told you have 60, maybe less, maybe more prevalence of diastolic dysfunction. Some of them will have actually frank heart failure that is just not known to us. There is a chance you'll actually have fewer of the events that are heart failure-related, whether it's an ER visit, hospitalization, a stroke.
Marat, can I ask you a quick question? Just because I saw the same reaction when you showed PV loops as every medical student about to pass out from boredom.
I actually thought they were pretty good. Those PV loops were very compelling, that there is a significant improvement in the physiology. If that's the underlying physiology, that's got to translate into lower event rates, at least rehospitalization and easier management.
Absolutely.
I mean, the afterload that you showed the elastance change is in and of itself, that was
I mean, beyond an SBP change. It would be one thing if the blood pressure changes, but here the pressures and the volumes change in a favorable direction. Meaningful, not just a little bit. I mean, a couple points in a wedge pressure reduction is a big deal in a healthy individual. It will be even larger in a heart failure patient. I think if everything moves the right way, that was a magnificent change. But the key part is acute, and then I'll show you also six-month data. If those things continue to be consistent, we know that lowering blood pressure in this population likely will not resolve their harm, but actually we're seeing the opposite, that it sort of stacks. It's all the benefits start stacking, and in the right patient population, will result in better outcomes.
Just
I think that
Just sorry to interrupt. In the middle of the trial, in the early part of the trial, we did accept NYHA class II patients, so getting some little more symptomatic, and we've included KCCQ, which is a heart failure questionnaire and quality of life questionnaires. This study is not going to be a one-year study. This study is going out to three and likely four or five years. We'll be following these patients for a long time. I think the data that comes out, the top-level data that will come out in May of next year is going to be exciting. The gift that's given is this is a trial that wasn't designed for regulatory approval. This is a trial that was designed to be standard of care and change medicine. There's a lot that's going to come over time.
One other thing I'll add is, that I'm going to be looking for, certainly the changes in chamber dimensions, LV volumes, and even LA volumes. But one of the other aspects, as an electrophysiologist, we could potentially see less atrial fibrillation, less burden of atrial fibrillation, because there's nothing that's more myogenic than atrial stretch. If it actually is decreasing, so that's another area that I think we'll be sort of focused on.
Maybe one more question to Allen, then I'll wrap up. We're going to have this group in our cocktails, so hopefully, we won't get to every question, but if you can get to one of the doctors, corner them, and get your questions in. But Allen, we showed data with PK at 13 now per milligram in terms of our animal data versus one for stent. Does anything about that concern you? I'll ask the other part of it, does anything about that excite you? And Duane too, in terms of that question.
I'll take the excitement part if you want to take the concern part.
I'll take the concern part first.
Okay. All right.
My understanding is that the only way to die of sirolimus is if somebody drops a big bag on your head. At least basically, which hopefully won't happen in the cath lab, right?
We had one accident today, but we don't have a bag of sirolimus, so I think we're going to be okay.
The therapeutic window is enormous, right? It is a very, very safe drug. It has been around forever, like you say. And there is basically no downside.
That sounded like the excitement part to me.
No, that was the negative part.
No, I do not have anything to add to that. I mean, that was the good part. I mean, there really is a very wide therapeutic range for sirolimus. The downside is when you fall below the therapeutic level, as Allen showed nicely in his slides, which were great, by the way. I think that we both are answering the same way because I am unconcerned, and I just do not want it to fall below so that we have the same problems that we had, for example, when we used therapies that were not therapeutic.
I think I was going to make a few comments, but we had questions about reimbursement. I think on both programs, one of the things that we've talked about to investors is the reimbursement setup is, we think, one of the most exciting things for both of these therapies. Pacemakers are reimbursed. We do have Breakthrough Device Designation. We see upside on that. That's something that we're working through in terms of how we're going to pursue it. The same thing, though, is true for uncoated balloons. And one of the things we're seeing as new devices are coming to the market is the NTAP, TPT, we're seeing those codes become permanent. And ultimately, that's actually affecting how some of our competitors are timing their commercialization to make sure the permanent reimbursement applies. That's another thing.
A question we had a couple times was, are we going to find a partner for Virtue? We are committed to our partnership business model. The strength of our balance sheet, though, gives us flexibility to think about when we do that, how we do that. We think there's a rich landscape, and we think that people here that don't work in that side of Medtronic, it includes Medtronic. But at the end of the day, we'll do that at the right time, in the right way. We're thrilled about the partnership we have with Medtronic, and please find Rob or Chris or Matt. You can talk to them directly. Hopefully, we'll hear, we expect to hear more from Medtronic directly as we move to the data, and we expect to be talking about that data together. There's a lot more questions here that we're not going to get to.
I'm going to just say thank you all for being here. Thank you for being online. Most importantly, thank you guys for the work you're doing with us and for taking the time to share your thoughts, share the presentations, and have this discussion. I wish we could go on for another hour, but we've got people to feed and drinks to have. Enjoy if you're not here, but thank you guys so much.